PIK3CG and plasma cell myeloma: A novel specific inhibitor, S14161, inhibits D-cyclin transactivation via the PI3K signaling pathway to exert anti-myeloma activity [26], while displaying no gross toxicity at concentrations up to 500 mg/kg in an in vivo assay, making it a probable drug candidate.